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The concept of pericyte has been changing over years. This cell type was believed 
to possess only a function of trophic support to endothelial cells and to maintain 
vasculature stabilization. In the last years, the discovery of multipotent ability of 
perivascular populations led to the concept of vessel/wall niche. Likewise, several 
perivascular populations have been identified in animal and human bone marrow. 
In this review, we provide an overview on bone marrow perivascular population, 
their cross-talk with other niche components, relationship with bone marrow stromal 
stem cells, and similarities and differences with the perivascular population of the 
vessel/wall niche. Finally, we focus on the regenerative potential of these cells and the 
forthcoming challenges related to their use as cell therapy products.
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Regenerative medicine is a common term 
used in identifying the field of research that 
focuses on employing the techniques in test-
ing the ability of regeneration and restora-
tion in damaged cells, tissues or organs in 
restoring functionality. This field of medi-
cine is consistent of four distinct fields: cel-
lular therapy, tissue engineering, gene ther-
apy and biomedical engineering. In recent 
years, application of cellular therapy has 
gained great attention thanks to a plethora 
of exciting findings in the fields of stem and 
 progenitor cell research.
Stem cells, as the identifiable members in 
the field of cellular therapy, are well known 
for their abilities of self-renewal and direct 
differentiation. More distinctly, the cohort of 
embryonic stem cells (ESCs), induced pluri-
potent stem cells (iPSC) or adult circulating 
and resident stem cells are well character-
ized as viable options for their application 
in the fields of preclinical and translational 
research [1]. The latter category, adult stem 
cells, can give rise only to cells of a given 
germ layer and are thus listed as multi potent. 
The field of vascular regeneration aims at 
the restoration of normal vascular structure 
and function via the formation of new ves-
sel (vasculogenesis) or the sprouting from 
the pre-existing ones (angiogenesis). Several 
multipotent cells have been proposed for the 
therapeutic applications of vascular regenera-
tion in relieving the symptoms of ischemia, 
prevention of hypoxia-related tissue dam-
age and avoidance of well-known vascular 
complications such as thrombosis, dissec-
tion or capillary leakage. Unfortunately, in 
spite of promising initial in vitro and ex vivo 
results, the adult stem cells failed to deliver 
an equally positive outcome in clinical stud-
ies [2,3]. From this point of view, endothelial 
progenitor cells (EPCs) offer a paradigm 
of this development. Characterized for the 
first time in 1997 by Asahara et al. [4], EPCs 
have shown that they can contribute to neo-
vessel formation, wound healing and inti-
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mal re-endothelialization [5]. Unfortunately, a lack of 
standardization led to mixed results in their poten-
tial therapeutical applications [6]. This failure can be 
attributable to the presence of different isolation proto-
cols, the lack of consensus about a precise antigen char-
acterization, and the lack of a functional assay to define 
cell role and properties [7]. If a lesson could be learned 
from the EPC story it is that a scientific consensus is 
needed in identifying the phenotypic and functional 
properties of the noted cells for the establishment of a 
standardized isolation, characterization and culturing 
protocols for their future applications in clinical trials.
Parallel with the fall of the EPCs, the idea that vas-
cular progenitor cells reside in the vessel wall emerged. 
Many reports identified similar populations isolated 
from different tissue with angiogenic potential though 
without endothelial lineage commitment [8–15]. Those 
populations can be identified among the broad group of 
the mural cells. Due to their perivascular position and 
their multilineage potential, they can be considered 
the in situ equivalent of bone marrow (BM) mesen-
chymal stromal cells (MSCs) or as perivascular stro-
mal cells (PSCs) (Table 1). In recent years, an incred-
ible number of findings have been gathered about these 
populations, and the concept of mural cell has evolved 
accordingly [16]. The BM is the main reservoir of stem 
and progenitor cells during adulthood. It has received 
particular attention as the architecture of the tissue is 
yet to be clearly elucidated. Additionally, in the periph-
eral vascular wall, different kind of perivascular popu-
lation, which respond to different functions have been 
characterized, isolated and expanded, opening a huge 
debate on vascular progenitor cell hierarchy [17–20].
In this review, we aim to provide an overview of the 
main perivascular players in the BM, how they inter-
act with other BM populations and influence the tissue 
structure. In addition, we discuss the stem/progeni-
tor features and therapeutic potential of those cells, 
which could be exploited as a novel product in the 
 regenerative medicine field.
Pericytes revised
For years, pericytes were believed to be important 
just for their role in trophic support and stabilization 
to the vasculature. They share a common basement 
membrane with endothelial cells (ECs), and both pro-
duce basement membrane factors [25]. They are not 
completely separated from ECs but contact through 
cell junctions: the peg–socket interaction where peri-
cyte cytoplasmic ‘pegs’ insert into EC invaginations; 
the gap junctions that allow diffusion of signaling 
factors; and the adhesion plaques that anchor cells to 
the basement membrane [26]. The density of pericytes 
in the body is tissue-specific, and the EC-to-pericyte 
ratio ranges from 1:1 (in the brain) to 10:1 (in skel-
etal muscle), while the normal pericyte coverage on 
the endothelium ranges from 10 to 70%. This dis-
tribution appears to have a relationship with the vas-
cular permeability barrier, endothelium turnover and 
blood pressure [27,28]. There is a continuum of vascular 
smooth muscle cell/pericyte structure from arterioles 
to venules [27].
The common idea of pericyte has been revolution-
ized in the last recent years. In the first instance, aside 
from microvascular pericyte other perivascular popu-
lations have been discovered. If while microvascular 
pericyte normally resides in the tunica media, adventi-
tial cells have been characterized in the tunica adven-
titia [8–10,29]. They share a common antigenic profile 
with microvascular pericytes, although the two popu-
lations can be distinguished according to differential 
expression of some exclusive markers. Both popula-
tions have been systematically isolated from different 
tissues, demonstrating an embryogenic continuity 
among them. Most importantly, both cells are proven 
to have a multipotent lineage commitment. Another 
group of progenitor population has been identified in 
the tunica intima, even although they cannot be con-
sidered proper perivascular cells [23]. These populations 
are characterized by an endothelial lineage commit-
ment to a different extent. A side population isolated 
in a murine model showed a greater clonogenic and 
angiogenic capacity than mature ECs and formed 
functional vessels in vivo [22]. Another study identified 
the myogenic ECs, a rare subset of myogenic precur-
sor cells that co-expresses myogenic and EC markers 
(CD56, CD34, CD144) at the microvascular level [24].
The discovery of these populations supported the 
idea that blood vessels may contain their own multi-
potent resident population, able to regenerate small 
and large vessels as well as surrounding tissue. Thus, 
the idea of a vessel wall niche has become widely 
accepted [16]. In preclinical studies, those populations 
have demonstrated a regenerative angiogenic,  myogenic, 
 chondrogenic and osteogenic  potential [16,30,31].
BM spatial & functional organization
The BM is a spongy tissue encapsulated within bones 
involved in hematopoiesis for the production of blood 
cells in the red marrow of flat and long bones; yel-
low marrow is found in the medullary cavity and 
consists of adipocytes. BM is encased in vascularized 
and innervated bone with trabeculae projecting in the 
metaphysis. The medullary cavity is lined by endo-
steum that consists of bone-forming osteoblasts and 
bone-resorbing osteoclasts [32]. Arteries enter through 
foramina nutricia and coalesce into venous sinusoids 
made of a single layer of ECs that act as a conduit to 
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the circulation [33]. In order to mature, hematopoi-
etic stem cells (HSCs) reside in hematopoietic niches. 
Those are specialized microenviroment which provides 
the support and signals needed for the differentiation 
of HSCs into mature cells. The niches relocates dur-
ing fetal development from yolk sac to aorta–gonad– 
mesonephros region, then to placenta and fetal liver, 
and finally to BM, which is the specialized tissue in 
adult life for hematopoiesis. In the niches different 
stromal cell and extracellular matrix surround the 
HSCs in order to regulate their mobilization, differen-
tiation and quiescence [34,35]. The two distinct niches 
include the endosteal niche, lining the bone surface, 
and the vascular niche around sinusoids.
The endosteal niche
HSCs in the endosteal niche exhibit a maturation gra-
dient, with more committed progenitors centrally, and 
primitive HSCs with greater proliferative potential 
at the endosteum [36]. Osteoblasts may not maintain 
HSCs directly but by secreting factors. Transplanted 
HSCs into irradiated wild-type mice migrated to the 
endosteum, indicating indirect effects of osteoblasts, 
as high ionic calcium concentrations attract calcium-
sensing receptors on HSCs [37]. HSC maturation is 
regulated by Notch signaling with osteoblasts, and 
osteoblasts secrete SCF for HSC self-renewal [38]. The 
Tie2 receptor binds Ang-1 produced by osteoblasts to 
maintain HSC quiescence [39,40]. Studies that increased 
osteoblasts by strontium only found a late increase in 
HSCs, further suggesting an indirect role [41].
Osteoclasts, which differentiate from precursor cells 
via RANKL, regulate HSC mobilization, especially 
under inflammation or hypoxia. RANKL is a type 
II membrane protein on osteoblasts and Kollet et al. 
found the stimulation of osteoclasts induced the egres-
sion of HSCs via CXCR4 and MMP-9 [42]. In addi-
tion, SDF-1α and osteopontin were reduced leading to 
HSC egression. However, RANKL did not stimulate 
mobilization with impaired osteoclasts under stress 
stimuli, highlighting a role of osteoclasts in regulating 
HSC recruitment and homeostasis [43].
Table 1. Vascular progenitor populations.
Study (year) Tissue of extraction Isolation protocol Markers Ref.
Microvascular pericytes
Covas et al. (2008) Human retina Flow cytometry sorting for 
CD146
NG2+, CD146+, CD271+ and 
CD140B+
[12]
Dellavalle et al. 
(2007)
Human skeletal muscle Culture adherence selection ALP+, desmin+, α-SMA+, 
vimentin+ and PDGFRβ+
[13]
Crisan et al. (2008) Human fetal skeletal muscle, 
human fetal pancreas, human 
placenta, human umbilical cord 
and other tissues
Flow cytometry sorting for 
CD146 and ALP
CD146+, CD34-, CD45- and CD56- [14]
Zimmerlin et al. 
(2010)
Human adipose tissue Flow cytometry sorting for 
CD146, CD45 and CD31
CD146+, α-SMA+, CD90+, CD34- 
and CD31-
[21]
Adventitial cells
Campagnolo et al. 
(2010)
Human saphenous vein Immunomagnetic sorting for 
CD31 and CD34
CD31-, CD34+, CD146- and vWf- [8]
Corselli et al. (2012) Human adipose tissue Flow cytometry for CD146, 
CD34 and CD31
CD34+, CD31-, CD146- and CD45- [9]
Avolio et al. (2015) Human neonatal heart Immunomagnetic sorting for 
CD31 and CD34
CD44+, CD105+, CD146-, CD34+, 
CD31- and CD45-
[15]
Hoshino et al. 
(2008)
Human pulmonary artery Culture adherence selection Vimentin+, collagen type-1+, 
CD29+, CD44+ and CD105+
[10]
Intima cells
Naito et al. (2012) Murine liver, lung, heart and 
skeletal muscle
Tissue digestion with 
collagenase II and dispase
CD31+, CD45- and Sca-1+ [22]
Fang et al. (2012) Murine lung Flow cytometry sorting lin-, CD31+, CD105+, Sca1+ and 
CD117+
[23]
Zheng et al. (2007) Human skeletal muscle Flow cytometry sorting CD56+, CD34+ and CD144+ [24]
Table recapitulating the progenitor population of the vessel-wall niche. Three main group of progenitors can be identified according to their localization in the vessel layers.
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Among the diverse group of cells in the endosteum, 
macrophages also regulate HSCs. Granulocyte colony-
stimulating factor suppresses osteoblasts and SDF-1α 
expression promoting HSC mobilization [44,45]. This 
mobilization is further enhanced as GCS-F depletes an 
endosteal macrophage population called ‘osteomacs’, 
which support osteoblasts [46]. Together, this suggests 
the involvement of endosteal region in multiple cellular 
interactions controlling HSCs.
The vascular niche
HSCs in the vascular niche are associated and influ-
enced by a variety of different cell type. ECs contrib-
ute to HSC biology, primarily through the produc-
tion of angiocrine factors. Akt and p42/44 MAPK are 
cell- regulating pathways. Akt activation in ECs, both 
in vitro and in vivo, promotes HSC expansion and 
self-renewal through upregulation of factors includ-
ing IGFBP2, FGF2, BMP4 and DHH, and in parallel 
the downregulation of HSC-inhibitory factors dick-
kopf WNT signaling pathway inhibitor 1 and Ang2. 
MAPK-activated ECs have contrary effects by dif-
ferentiating HSCs when HSC-stimulating factors are 
downregulated. However, co-activation of Akt and 
MAPK ECs increases Notch ligands to prevent exhaus-
tion of HSCs and accelerates differentiation [47]. Thus, 
the control of Akt and MAPK activation by angio-
crine factors can regulate HSC homoeostasis. Akt 
can be activated by pericyte-derived Ang1 and inhibit 
EC apoptosis, and is implicated in insulin-stimulated 
glucose uptake [48]. Along with a paracrine action, 
ECs can interact in a cell-to-cell contact with HSCs. 
E-selectin, exclusively expressed by BM ECs, is needed 
to maintain  quiescence in HSCs [49].
The other main regulator of the vascular niche is 
represented by the heterogeneous group of MSCs. Sub-
sets of different perivascular MSCs have been identified 
and investigated in the last few years. These cells local-
ize adjacent to marrow vessels and can be identified by 
different markers besides the typical mesen chymal ones 
(CD105, CD90, CD73). They can express CD146 [19], 
CXCL-12 [18], Nestin [50] and Leptin receptor (LepR) 
(Figure 1) [51]. All these populations have in common 
the secretion of the factors needed for HSC main-
tenance: CXCL-12 and SCF. Wild-type perivascular 
cells synthesize SCF and support hematopoiesis only 
when implanted into defective S1/S1d murine cells and 
not separately, suggesting cell–cell contact is required 
for HSC maintenance [52]. In particular, HSCs need 
cell-to-cell interaction with perivascular cells as HSCs 
were depleted in Sl/Sld mutant mice, which express 
the soluble form of SCF but not the membrane-bound 
one [53]. SCF supply to the niche microenvironment is 
shared with ECs. In fact, deletion of SCF from LepR+ 
PSCs or ECs depletes HSCs [51], while deletion from 
osteoblasts, HSCs or Nestin+ BM cells showed no 
effect on HSC population [51]. The other key factor is 
represented by CXCL-12. One of the first perivascular 
populations to be identified was indeed the CXCL-12 
abundant reticular (CAR) cells in the seminal work 
from  Sugiyama et al. [18]. Deletion of CXCL12 from 
osteoblasts has no effect on HSCs, while deletion of 
CXCL-12 from osterix-expressing stromal cells, which 
include CAR cells and osteoblasts, results in constitutive 
HSC mobilization. CXCL-12 deletion from ECs results 
in a modest loss of long-term repopulating  activity [54].
The HSC niches are not regulated by a single com-
ponent but by the combination of multiple cells. The 
nervous system exerts an overall control over the cel-
lular interactions. Circadian noradrenaline release 
from sympathetic nerves synapsing on perivascular 
cells regulates the release of SDF-1α and the mobili-
zation of HSCs [55,56]. The nervous system also acts 
directly on HSCs as CD34+ cells express dopamine 
and β2-adrenergic receptors [57].
BM pericytes: a heterogeneous & diverse 
population
As discussed in the paragraph above, the vascular niche 
is characterized by the presence of different perivascu-
lar populations [58]. In recent years, populations with 
similar antigenic profile have been studied both in situ 
and expanded ex vivo. They can be mainly divided in 
two main groups according to their anatomical posi-
tion (Table 2). This spatial disposition can remind the 
organization of the vessel-wall niche. Likewise, a third 
progenitor population can be identified in the intima 
of BM vessel (Figure 1).
Perisinusoidal population
CD146 also known as melanoma cell adhesion mole-
cule (MCAM) is normally expressed by pericyte from 
microvessels and capillaries whereas its expression is 
lacking in mural cells isolated from tunica adventitia. 
Among the heterogeneous population of BM MSCs, 
CD146 in combination with other markers define a 
perivascular population with a pivotal role in vascular 
niche maintenance and reconstitution [61].
In 2007, Sacchetti et al. were the first to demonstrate 
the existence of a clonogenic CD146+ perivascular frac-
tion of MSCs [19]. In an elegant study, authors demon-
strated that the ability to form an in vivo heterotopic 
niche (bone and marrow) was a prerogative of human, 
nonhematopoietic BM MSCs. In particular, this popu-
lation strongly expressed marker CD146. However, not 
all the BM MSCs were able to express this marker but 
only the colony-forming unit fibroblasts (CFU-F) cul-
tures and their clonal progeny [19]. In particular, CFU-
www.futuremedicine.com 887
Figure 1. Spatial organization of bone marrow niches. Cartoon illustrating the organization of the vascular and 
endosteal niches and the distribution of the perivascular population. Periarteriolar cells are located atop the 
intima of the larger vessel and they secrete SCF and CXCL-12 factor in order to maintain HSCs in a quiescent state. 
Perisinusoidal cells are located around capillaries. They exert a regulation over proliferative HSCs ready to enter 
the blood stream through the fenestrated BM endothelium. HSCs located in the endosteal niche and around 
the adventitia of arterioles are less oxygenated and thus less exposed to ROS. This distribution creates an ROS 
gradient in which dormant HSC localize accordingly.  
BM: Bone marrow; HSC: Hematopoietic stem cell; ROS: Reactive oxygen species; SCF: Stem cell factor.
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Fs were localized in the CD146+/CD45- fraction. These 
cells show the ability to act as a mural cell in co-culture 
with ECs. In in vivo transplantation, CD146+ acquire 
the same phenotype of Sugiyama CAR cells, suggesting 
they may be their in vitro counterpart [19]. The support to 
the hematopoietic microenvironment was mainly regu-
lated by the secretion of Ang-1 [19]. In 2011, Tormin et al. 
provided a better characterization of the CD146+ MSCs 
fraction. They demonstrated that CFU-F cultures were 
mainly enriched for CD271+/CD45-/CD146-/low and 
CD271+/CD45-/CD146+ cells, which were both char-
acterized by a typical mesenchymal tri-lineage poten-
tial, and both were able to reproduce bone and hemato-
poietic stroma in in vivo transplantation. Interestingly, 
the expression of CD146 was inversely correlated with 
hypoxia, providing an explanation why in situ CAR 
express CD146 while bone lining CD271+ MSCs do 
not [17].
Beyond the ability to recreate bone and marrow 
stroma in orthotopic and heterotopic transplantation, 
CD146+ MSCs play a key role in HSCs maintenance. 
Corselli et al. showed that CD34-/CD45-/CD146+ 
perivascular cells support stemness in human HSCs 
ex vivo, but unfractionated MSCs and CD146- cells 
induce differentiation jeopardizing HSCs’ ability to 
engraft [20]. CD34-/CD45-/CD146+ cells were effec-
tive to sustain hematopoiesis from both BM and 
nonhematopoietic adipose tissue acting via cell-to-
cell contact mediated by Notch ligands [20]. Another 
signaling mechanism involved in HSC maintenance 
could be related to the Wnt pathway. In a recent study, 
He et al. demonstrated that a BM osteogenic precur-
sor (Nestin+, Lepr+, Sca-1+, CD146+) can support long-
term HSCs by the secretion of SCF and IL-11, and the 
inhibition of Wnt signaling in a Notch-independent 
mechanism [62]. This highlights a ubiquitous ability of 
pericytes not restricted to the BM.
CD146+ and CD146-/low cells demonstrated a simi-
lar antigenic profile in different studies. Both popu-
lations expressed typical MSCs markers (CD105, 
CD73, CD90), even though the CD146 fraction could 
express α-smooth muscle actin at a low level. The dif-
ference in CD146 expression did not affect the abil-
ity to differentiate into adipocyte, chondrocyte and 
osteoblasts as MSCs. However, in a recent study Esp-
agnolle et al. showed that CD146+ but not CD146-/low 
clones of CFU-Fs are associated with commitment to 
vascular smooth muscle lineage as demonstrated by the 
upregulation of CD49α, calponin-1, smooth muscle 
 protein 2α and elastin [63]. Those differences translated 
into functional properties: CD146+ clones were able to 
secrete more matrix than CD146-/low ones. Interest-
ingly, TGF-β1, a key factor in vascular smooth muscle 
cell differentiation, upregulated CD146 expression 
whereas FGF-2, an angiogenic factor, downregulates 
it [63]. Moreover, CD146- cells in the marrow contain a 
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subpopulation with fibroblast properties and a peculiar 
pattern of cytokine production (i.e., CD318) [64].
Periarteriolar population
Along with CD146, perivascular populations in 
humans and mice have been characterized for the 
expression of intermediate protein filament nestin. In 
2010, Mendez-Ferrer et al. identified for the first time a 
Nestin+ population in the perivascular marrow [50]. This 
population express high levels of CXCL-12 and Ang-1 
but lacks endothelial markers such as CD31, vascular 
endothelial cadherin or CD34 [50]. Interestingly, this 
population is positive for the β-adrenergic receptor and 
anatomically associated with catecholaminergic nerve 
fibers, suggesting they can act as a regulator of HSC 
trafficking [50]. As MSCs, Nestin+ cells retain the abil-
ity to differentiate in vitro into adipocytes, chondro-
cytes and osteoblasts, while clono genicity of MSCs is 
retained only in the CD45-/ Nestin+ fraction [50]. Nes-
tin+ cells have also the ability to maintain the HSC 
niche. Deletion experiments led to depletion of CD48-
Lin-Sca-1+c-kit+ (LSK) cells and CD150+ CD48− LSK 
cells in the marrow and relatively increased these 
populations in the spleen, suggesting Nestin+ cells are 
involved in stem cell trafficking [50].
A 2013 study further investigated the relationship 
between Nestin expression and functional proper-
ties of the the vascular niche. Kunisaki et al., using 
Nestin-GFP mice demonstrated nestin is highly 
expressed in arterioles (Nesperi), while perivascular 
reticular cells closely related to sinusoids are associated 
with a dim expression (Nesretic) [59]. Even though the 
latter population was the most abundant in the mar-
row, Nesperi retained the most clonogenicity in CFU-F 
assay [59]. Nesperi cells were also associated with tyro-
sine hydroxylase- positive sympathetic nerves and glial 
fibrillary acidic protein-positive Schwann cells, simi-
larly to previous studies [50,59]. Using a triple transgene 
mouse model, authors identified a correlation between 
spatial localization and functional organization of dif-
ferent perivascular cells: Nesreti expressing LepR are sit-
uated near the sinusoids and have a higher proliferation 
rate; Nesperi are localized near the arterioles, express 
neural/glial antigen 2 and α-smooth muscle actin, 
and demonstrate a more quiescent state [59]. The latter 
population has also the ability to maintain HSCs in 
a dormant state, while the Nesretic LepR+ NG2+ popu-
lation maintains more mature HSCs [59]. In a recent 
study, Ciuculescu et al. demonstrated that the Nestin+ 
population exerts a functional control on HSCs via 
Rac GTPases. Nestin-Cre-directed excision of Rac1 in 
Rac3-/- mice reduced Nestin+ cells, leading to a drastic 
decrease of arterioles and conversely an increase in sinu-
soidal mass. The deletion also encompassed a reduction 
in long-term HSCs, CFU-Fs activity, and circulating 
progenitor cells suggesting Nesperi cells are in contact 
with the main reservoir of quiescent HSCs [65].
Mesodermal progenitor cells
Among BM Nestin+ populations, a different subset 
of MSCs has been recently isolated. Replacing fetal 
bovine serum with pooled human serum and thanks 
Table 2. Bone marrow perivascular population.
Study (year) Tissue of 
extraction
Isolation protocol Markers Ref.
Perisinusoidal cells
Sacchetti et al. (2007) Murine BM Adherence selection and flow 
cytometry sorting
CD45-CD146+ [19]
Tormin et al. (2011) Human BM Colony-forming assay lin-, CD271+, CD45- and CD146+ [17]
Corselli et al. (2013) Human fetal BM Flow cytometry sorting for CD146, 
CD45 and CD34
CD146+, LepR+, vWF-, CD45-, 
CD34- and CXCL-12+
[20]
Periarteriolar cells
Mendez-Ferrer et al. (2010) Murine BM CD45 immunomagnetic depletion 
in combination with mesensphere 
assay
CD45-, Nestin+ [50]
Kunisaki et al. (2013) Murin BM Colony-forming assay CD45-, Nestin+, NG2+ [59]
Intima cells
Petrini et al. (2009) Human adult BM Cell adherence selection Nestin+, CD31+, CD105+, CD90-, 
CD73-, CD271-
[60]
Table recapitulating the characterized and isolated perivascular population of the vascular niche in the BM. As in the wall-vessel niche, three main groups of cells can 
be distinguished.
BM: Bone marrow.
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to selective culture conditions, Petrini et al. character-
ized a rounded, fried egg-shaped population [60]. These 
cells were positive for Nestin, CD31 but they lack the 
expression of MSC markers, CD73, CD90, CD166 
and CD271, while retaining the expression for CD105. 
If supplemented with fetal bovine serum, this popula-
tion gave rise to an MSC progeny [60]. Interestingly, 
they were positive for pluripotency-associated tran-
scription factors Oct-4, NANOG and to a lesser extent 
c-MYC but they lacked typical MSC markers, such as 
RUNX2 and Sox2 [66]. This population, named meso-
dermal progenitor cells, is thought to be an early MSCs 
and, even if the in situ localization has not been yet elu-
cidated, it is likely that they reside in the tunica intima 
of BM vessels, in contact with CAR cells or the Nesperi 
population. Their positivity for CD31 and Nestin 
accounts for the hypothesis of a primitive  progenitor 
for endothelial lineages [66,67].
Similarities & diversity with vascular wall niche
The architecture of the perivascular population in the 
BM vascular niche could directly recall the one of PSCs 
in the vessel wall; even if some anatomical differences 
have to be considered. As described above, the vessel 
wall niche is constituted of two different populations, 
a microvascular fraction residing atop the tunica intima 
of small and large vessels and an adventitial fraction 
located in the tunica adventitia of larger vessels. In the 
BM, there is a certain degree of equivalence: the perisi-
nusoidal population is directly in contact with ECs and 
it expresses CD146 as do microvascular pericytes [17,19]. 
On the other hand, periarteriolar population lacks the 
expression of this marker as do the adventitial cells and 
they reside near vessels of the same caliber [59,65]. Inter-
estingly, the lack of the marker in the adventitial pro-
genitor cell (APC) population could be explained in the 
same way of BM periarteriole cells: likely, it is due to the 
fact that periarteriolar cells are the less oxygenated cells 
in the vessel wall. The production of reactive oxygen 
species is inversely proportional to hypoxic conditions. 
Reactive oxygen species are a main regulator of stem cell 
quiescence [68,69]. Not surprisingly, the more dormant 
cells are located near the periarteriolar space rather than 
the more oxygenated sinusoids [59]. Thus, it is hypothe-
sized that APCs can work as a reservoir to reconstitute 
the other perivascular population. Some findings sup-
port this ‘centripetal’ interpretation. Iacobazzi et al. 
demonstrated that APCs have a higher resilience to 
oxidative stress than ECs, resembling the periarteriolar 
cells [70]. However, no direct comparison with micro-
vascular pericytes was carried out. Moreover, there are 
findings that demonstrate in vitro expanded APCs can 
acquire a microvascular pericyte phenotype [9]. Consid-
ering all these findings, could the BM vascular and ves-
sel-wall niche be considered as an equivalent system just 
located in a different district? Certainly, at the moment 
we are far from having a definitive answer. However, 
the BM niches preserve some exclusive characteristics 
when compared with its peripheral counterpart. First, 
both perisinusoidal and periarteriolar cells have the 
ability to support and maintain the HSCs compart-
ment [20,59]. It is not clear if this specialization could be 
explained because of the particular BM microenviron-
ment. Micro vascular pericyte isolated from other tissue 
other than BM showed in vitro but not in vivo ability to 
support hematopoiesis [71]. Second, it has been observed 
that ectopic transplantation of BM perivascular cells 
in vivo reproduces the hematopoietic niche [72,73]. It is 
thus arguable that when in vitro artifacts are taken into 
account, the perivascular cells from the BM niche can 
represent a progenitor of other tissue PSCs.  Alternatively, 
they may be derived from a common ancestor.
BM perivascular cell stemness 
& regenerative potential
MSCs & pericytes, parents or siblings?
In recent years, the concept of pericyte has undergone 
several revisions. Pericytes were primarily identified 
as mural cells with structural and scaffolding proper-
ties, able to promote and then stabilize the vasculature. 
As a more thorough investigation progressed, pericyte 
populations have been characterized in different tissues. 
More interestingly, different kinds of perivascular cells 
with different functions/properties have been identified 
in the same vasculature. The family of mural cells was 
enriched with APCs, microvascular pericytes and so on. 
All these populations have been linked to BM MSCs, 
because they share a similar antigenic profile and multi-
lineage potential. However, as for BM MSCs, pericytes 
have to be considered an heterogeneous population, 
and a better definition of sub populations and subsets 
is needed to elucidate  relationships among those cells.
At present, there is an open debate about progenitor 
hierarchy between MSCs and pericytes, and the in vitro 
characterization brings another level of complexity in this 
scenario. In fact, the in vivo perivascular location com-
bined with the immunocytochemical characterization 
is widely accepted for bona fide identification. In vitro, 
the expression of pericyte-related markers and supportive 
position in the formation of capillary-like structures by 
ECs are considered sufficient to define a population as 
pericyte [74]. The definition of protocols to isolate peri-
cytes (CD146+CD34-CD45-) and adventitial progeni-
tor cells (CD146-CD34+CD45-) from different tissues 
and their similarities to MSC group led to the hypothe-
sis that all MSCs could act as pericytes [75]. However, 
Blocki et al. demonstrated that not all the MSCs are able 
to act as pericytes, but only particular MSC subsets [76].
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Recently BM perivascular cells entered the stage in 
this controversial scenario. The multitude of differ-
ent populations characterized in vitro and in vivo in 
murine and human BM suffers from the lack of stan-
dardization as MSCs. Indeed, the International Society 
for Cell Therapy (ISCT) definition presents differ-
ent limitations although it has been refined through 
the years [77]. Some populations as the CXCL-12+-
LepR+CD146+ (i.e., CAR) could be considered the 
equivalent of microvascular pericytes (CD34-CD146+) 
isolated from other tissues. On the other hand, at the 
moment Nestin+ periarteriolar population could be 
considered a functional peculiarity of BM tissue. A big 
question mark remains open also in BM: if those peri-
vascular/pericyte cell can be considered a subset of 
MSCs or, vice versa, should all the MSCs be enlisted 
in the perivascular family? The isolation of fibroblast-
like CD146+ populations with profibrotic properties 
along with the expression of this marker based upon 
the hypoxic condition (i.e., perisinusoidal cells express 
CD146 because they are the most oxygenated) leads us 
forward for the former hypothesis [78]. Surely, this is an 
issue that needs to be addressed in order to understand 
vascular and endosteal niche structure and progenitor 
cell hierarchy.
Interestingly, along with perisinusoidal cells  Tormin 
et al. identified a population of CD271+CD146- cells, 
which retains MSC properties but in vivo localizes in 
the trabecular bone-lining endosteal niche. Another 
criterion to ascertain the hierarchy between MSCs and 
PSCs could be plasticity. According to ISCT definition 
MSCs have to be able to differentiate in at least three dif-
ferent lineages (osteoblast, chondrocyte and adipocyte). 
Although it was demonstrated that they can differenti-
ate into many more, it is well known that nonclonal 
MSCs can fail to differentiate in the three classical line-
ages [79]. Similarly, the population characterized in the 
BM perivascular group (CAR, Nesperi, LepR+, among 
others) can differentiate into the three classical lineages 
but to a different extent [17,54] (Figure 2). For instance, 
CAR cells are more prone to a osteoprogenitor path 
and they tend to lose their adipogenicity through pas-
sages [17]. In addition, even if CD146+ perivascular cells 
are shown to support angiogenesis actively in vitro and 
in vivo, to date there is no proof that they can commit 
to an endothelial fate [17]. On the contrary, mesodermal 
progenitor cells, which lack some of the MSC features, 
are the most promising cells to achieve in vivo endo-
thelial differentiation [60]. Moreover, this population 
expresses stemness- related transcription factors such as 
Oct-4 and NANOG, while they are expressed only to a 
weaker extent in CD146+ cells, indicating to they may 
be the  potential mesenchymal ancestor of  perisinusoidal 
and  periarteriolar cells [60].
BM pericyte as regenerative tool
BM progenitor and stem cells have been widely used 
in animal models and clinical trials in the regenerative 
medicine field with mixed results. MSCs represented 
a promising cell therapy opportunity due to the possi-
bility to be isolated from various tissues. Additionally, 
their immunoprivileged status, multilineage poten-
tial and the ability to support angiogenesis in a para-
crine fashion make them attractive therapeutically [3]. 
Despite leading to some encouraging results in animal 
models, MSCs achieved controversial benefit when 
cell therapy was translated in humans [3]. The lack of 
protocol standardization and high cell heterogeneity 
may be accountable for these drawbacks [3]. BM peri-
vascular cells possess the same advantages of MSCs as 
they share antigenic and functional profiles, so that 
they could represent a particular subset of MSCs or the 
MSC ancestors. Several BM perivascular populations 
have been extensively characterized using additional 
markers and/or criteria on top of the ISCT MSC defi-
nition. This bypasses one of the major drawbacks of 
MSCs and offers the opportunity to use a more defined 
population in regenerative medicine applications. On 
the other hand, a higher level of antigenic details leads 
to a smaller population, which raises issues related 
to expansion, such as loss of multipotent status and 
occurring senescence [80]. Moreover, as observed in 
peripheral perivascular cells, biological background 
can affect cell reparative potential [78,81].
Currently, specific BM pericyte populations have 
been used in a limited number of studies. Tormin et al. 
demonstrate that lin-/CD271+/CD45-/CD146+ cells 
were able to induce the formation of bone, adipocyte, 
fibroblasts and capillaries in an immunodeficient mice 
model [17]. However, due to the heterogeneity of peri-
vascular populations, preliminary studies to investi-
gate and compare the potential of the different subsets 
are needed. In 2014, Gothard et al. isolated different 
clones from the MSC compartment, comparing their 
efficacy in vivo by subcutaneous implantation in nude 
mice. They observed that clones expressing Stro-1 and 
CD146 were the most effective in heterotopic bone 
formation, while CD105 expressing clones render 
modest results [82]. In another study, Harkness et al. 
compared flow cytometry sorted MSC-CD146+ ver-
sus MSC-CD146- isolated from human BM. Both 
groups were able to form bone and BM elements when 
implanted subcutaneously in nude mice. Interestingly, 
the CD146+ fraction showed a greater migratory abil-
ity both in vitro and in vivo [83]. Another issue to be 
addressed is the level of plasticity of these populations 
in comparison to similar ones isolated from different 
tissues. In a recent work, Hermann et al. compared 
CD34-CD146+ MSCs isolated from BM and adipo-
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Figure 2. Bone marrow perivascular cell multipotency. Recapitulating scheme of multipotent ability demonstrated 
in vitro and/or in vitro by BM perivascular cells. CD146- MSCs can acquire CD146 expression after exposure to 
normoxic condition. Similarly, in vitro cultured adventitial cell can phenotypically resemble microvascular pericyte. 
Perisinusoidal cells can differentiate in the classical tri-lineage of MSCs, although ability to commit to adipocyte 
fate is lost during in vitro expansion. Perisinusoidal cells can also acquire a VSMC-like phenotype after exposure 
to TGF-β, while a subset of CD146- MSCs has the ability to shift toward a fibroblast-like appearance. Also disease 
condition as heart failure can push BM CD146+ to acquire a fibroblast-like phenotype.  
BM: Bone marrow; MSC: Mesenchymal stromal cell; RA: Retinoic acid; VSMC: Vascular smooth muscle cell.
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cyte tissue. BM cells showed a better multipotent pro-
file, were superior to their fat tissue equivalent in chon-
drogenic regenerative applications while cells from 
the adipose tissue performed better in an osteogenic 
perspective [84]. This could be explained by the ability 
of CD146+ fraction to respond better to TGF-β stimu-
lation as discussed previously [63]. Additionally, BM-
derived perivascular cells were confirmed to promote 
more efficiently angiogenesis [84].
Apart from the regeneration ability linked to their 
multipotent lineage commitment, BM pericytes can 
contribute to the regenerative field favoring the recon-
stitution of the vascular niche in congenital immuno-
deficient disease. Mokhtari et al. demonstrated that 
transplanted human CD146+ BM cells could increase 
CXCL-12 production in the large animal fetal recipient, 
triggering HSC reconstitution [85]. That process could 
mimic a physiological one. Not surprisingly, Tasso et al. 
observed a recruitment of BM-derived CD146+CD105+ 
cells at the site of injection of MSCs [72].
Taken together, these data point out that BM peri-
cytes may reveal themselves as a versatile and useful 
product in regenerative cell therapy applications.
Conclusion
The concept of perivascular cells has evolved through 
years. Initially considered as simply scaffolding cell 
with the ability to promote and stabilize the vascula-
ture, pericytes are emerging as a heterogeneous multi-
potent progenitor population. As in other tissues, BM 
perivascular cells have been studied extensively, and 
two main populations have been identified: a perisinu-
soidal and a periarteriolar subtype. Interestingly, both 
populations play an important role in the maintenance 
of quiescent and proliferative HSCs through the secre-
tion of different factors (CXCL-12, SCF, IL-11, among 
others) or directly by cell-to-cell contacts involving 
Notch ligands in the process. The perisinusoidal sub-
type is comparable to microvascular pericytes, while 
the periarteriolar one shares some similarities with 
ACs. As their peripheral equivalent, those populations 
showed a multilineage commitment that could be 
exploited for regenerative purposes. Those populations 
are intertwined with the heterogeneous group of BM 
MSCs. It is likely MSCs and BM perivascular cells 
belong to the same group. Antigenic and functional 
differences among these populations could reflect the 
spatial organization in BM  architecture.
Future perspective
Due to their multilineage properties in combina-
tion with their ability to support hematopoiesis and 
angiogenic process, BM perivascular cells can be 
considered as a novel potential product in the field of 
regenerative medicine. Their ability to differentiate 
in osteo- and chondro- progenitors calls for in vitro 
and in vivo experimentation to pave the way to clini-
cal trials. Moreover, neo-intimal population i.e. meso-
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dermal progenitor cells showed to have the potential 
to be considered as endothelial progenitor cells. As 
discussed previously, hematopoietic support abil-
ity makes this population well suited as regenerative 
tool in congenital immunodeficient disease patients. 
However, as per any cell-based therapy, there are sev-
eral issues that need to be addressed. Firstly, basic 
science studies need to better define all the different 
perivascular population residing in the bone marrow 
in order to achieve a scientific consensus about them 
(i.e. pheno type characterization, population hierar-
chy). Then, in the perspective of BM PSCs as a regen-
erative tool, the possible impact of diseases should be 
investigated. For instance, it is known that condition 
as diabetes can provide epigenetic modifications which 
could affect regenerative efficacy. Finally, issues rela-
tive to senescence and expandability should be inves-
tigated. Those are key steps that need to be taken 
in order to not undermine the potential of a newly 
 discovered  regenerative tool.
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Executive summary
Perivascular stem cells
•	 Concepts of pericyte have evolved thanks to the discoveries of different perivascular populations with different 
properties.
•	 All these populations showed a multipotent ability. Thus it is widely accepted that vessels have their proper 
stem cell niche, the vessel-wall niche.
Bone marrow perivascular cells localization & function
•	 Bone marrow (BM) is functionally organized in two different niches: the endosteal niche lining of inner part 
of the bone and the vascular niche, localized around BM vessels.
•	 In the vascular niche, different perivascular populations have been characterized: perisinusoidal cells that 
exert maintenance on cycling hematopoietic stem cells ready to egress into vasculature, and periarteriolar 
cells, which maintain dormant hematopoietic stem cells.
BM perivascular cells stemness & regenerative potential
•	 Both cell types showed multilineage potential (adipogenic, chondrogenic and osteogenic) ability and common 
markers as mesenchymal stromal cells. Perisinusoidal cells are more prone to differentiate in osteoblasts and 
less in adipocyte than periarteriolar cells.
•	 There is an ongoing similarity between perivascular cells of the vessel-wall and BM vascular niche, even 
though BM cells retain tissue-specific properties.
•	 Thanks to their better characterized functional and antigenic profile, BM perivascular cells can be exploited as 
a regenerative tool in particular diseases (i.e., congenital immunodeficient diseases).
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